MAY 11, 2016 09:00 AM PDT

Keynote: Empirical Data on the Path to Genomic Medicine

  • Director, G2P Research Program (, Division of Genetics, Brigham and Women's Hospital, Broad Institute, Harvard Medical School
      Robert C. Green, MD, MPH is a medical geneticist and physician-scientist who directs the G2P Research Program ( in translational genomics and health outcomes in the Division of Genetics at Brigham and Women's Hospital, the Broad Institute and Harvard Medical School. Dr. Green is internationally recognized for designing and conducting empirical research that is accelerating the responsible implementation of genomic medicine. He led the first experimental trials disclosing common complex disease risk (the REVEAL Study) and one of the first prospective studies of direct-to-consumer genetic testing services (the PGen Study). He currently leads and co-leads the first randomized trials to explore the implementation of medical sequencing in adults (the MedSeq Project) and newborns (the BabySeq Project), respectively.


    In this time of incredible promise for genomic medicine, the Genomes2People (G2P) Research Program in Translational Genomics and Health Outcomes, directed by Robert C. Green, MD, MPH, is creating a deep body of knowledge on the medical, behavioral and economic implications of genomic analysis. Through its research, G2P is helping to set the stage for the use of genomic information in promoting health, preventing or mitigating disease, and reducing healthcare costs.

    Dr. Green will summarize his research program that for 15 years has focused on the collection of clinical outcomes data using multiple modalities, including randomized controlled trials (RCT), surveys, demonstration projects and other methodologies. Dr. Green will summarize key research studies and results that comprise the G2P Research Program. He will discuss the history of returning predictive genetic risk information, beginning with the REVEAL Study of returning APOE-related risks, and will present an overview of the projects that have rigorously tracked medical, behavioral and economic outcomes associated with evolving applications of genetic and genomic testing. These include: the PGen Study of consumer genetic testing; the MedSeq Project, a RCT exploring the integration of genome sequencing (GS) into the clinical care of healthy adults and adults with cardiomyopathy; the BabySeq Project, a RCT investigating the use of GS in screening healthy and sick infants for childhood risks and newborn illness; and the PeopleSeq Consortium, a longitudinal survey of ostensibly healthy cohorts that have received GS results. He will end by previewing upcoming initiatives and collaborations that are poised to inform the future implementation of genomic medicine, particularly in understudied populations and contexts with unique ELSI challenges.

    Show Resources
    Loading Comments...